Pegaspargase Other names: L-asparagine amidohydrolase Putative L-asparaginase precursor

Therapeutic indications

Pegaspargase is indicated for:

Acute lymphoblastic leukaemia (ALL)

Population group: only adults (18 - 65 years old)

Pegaspargase is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute lymphoblastic leukaemia (ALL)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Pegaspargase is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Pegaspargase is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV

History of thrombosis with L-asparaginase

H/O: thrombosis and additionally Asparaginase

History of pancreatitis

Pancreatitis

History of serious haemorrhagic events with L-asparaginase

Bleeding and additionally Asparaginase

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.